- Home
- PPBT vs KZIA Comparison
PPBT vs KZIA Comparison
Compare PPBT & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- KZIA
- Stock Information
- Founded
- PPBT 2010
- KZIA 1994
- Country
- PPBT Israel
- KZIA Australia
- Employees
- PPBT N/A
- KZIA N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- PPBT Health Care
- KZIA Health Care
- Exchange
- PPBT Nasdaq
- KZIA Nasdaq
- Market Cap
- PPBT 6.3M
- KZIA 5.1M
- IPO Year
- PPBT N/A
- KZIA 1999
- Fundamental
- Price
- PPBT $2.62
- KZIA $5.65
- Analyst Decision
- PPBT Strong Buy
- KZIA Strong Buy
- Analyst Count
- PPBT 1
- KZIA 2
- Target Price
- PPBT $33.00
- KZIA $57.50
- AVG Volume (30 Days)
- PPBT 30.8K
- KZIA 24.0K
- Earning Date
- PPBT 05-21-2025
- KZIA 06-17-2025
- Dividend Yield
- PPBT N/A
- KZIA N/A
- EPS Growth
- PPBT N/A
- KZIA N/A
- EPS
- PPBT N/A
- KZIA N/A
- Revenue
- PPBT N/A
- KZIA $1,655,324.00
- Revenue This Year
- PPBT N/A
- KZIA N/A
- Revenue Next Year
- PPBT N/A
- KZIA N/A
- P/E Ratio
- PPBT N/A
- KZIA N/A
- Revenue Growth
- PPBT N/A
- KZIA 248000.00
- 52 Week Low
- PPBT $2.00
- KZIA $2.86
- 52 Week High
- PPBT $13.95
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- PPBT 56.64
- KZIA 78.10
- Support Level
- PPBT $2.46
- KZIA $3.54
- Resistance Level
- PPBT $2.80
- KZIA $4.00
- Average True Range (ATR)
- PPBT 0.20
- KZIA 0.50
- MACD
- PPBT 0.04
- KZIA 0.25
- Stochastic Oscillator
- PPBT 66.96
- KZIA 86.07
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.